Technology convergence through partnerships, mergers and acquisitions is yielding a stream of strong candidates, finds Frost & Sullivan
MOUNTAIN VIEW, California, Nov. 17, 2015 /PRNewswire/ -- Next-generation monoclonal antibody-based platforms are gaining momentum and expected to impact patient care, particularly in the field of precision medicine. Antibody therapeutics are evidencing continuous evolution over time, especially in terms of its potency against disease targets, ability to treat more than one aspect of a disease simultaneously, enhanced and less expensive production processes as well as fewer side effects.
(Photo - http://photos.prnewswire.com/prnh/20151110/285827 )
New analysis from Frost & Sullivan, Advances in Monoclonal Antibody Therapeutics (http://bit.ly/1MHD9hs), finds monoclonal antibody therapeutics have received extensive attention in the past two decades. Currently, there are 50 monoclonal antibody drugs in the market and the competition among large biopharmaceutical companies is aggressive. More than 500 companies populate this space, developing novel discovery platforms and bioinformatics resources, among other products. Additionally, contract manufacturing companies are becoming increasingly popular. Overall, the global monoclonal antibody therapeutics market expects to expand at a compound annual growth rate of 8.1 percent during 2014 through 2020.
For complimentary access to more information on this research, please visit: http://bit.ly/1HDrWgM.
Monoclonal antibody therapeutics are being used for the treatment of a wide variety of diseases, especially in the following areas:
The development of new molecular agents with high specificity is playing a crucial role in the growth of the pharmaceuticals industry.
"Efforts to create advanced molecular agents indicate the top biopharmaceutical companies' strong focus on biologics," said TechVision Industry Analyst Cecilia Van Cauwenberghe. "However, during cell line generation, which is an important part of the molecular agent development process, it will be challenging to ensure the optimization of the cell expression system to increase capacity."
On the other hand, the approval of biologics may affect competing therapeutics. A significant concern for the competition is the cost of developing and producing biologics is remarkably higher than conventional small molecule medications. Additionally, there is a need for investments in biologics infrastructure and manufacturing.
Big pharmaceutical companies are advancing through potentially lucrative deals to acquire antibody technologies, compensating for patent losses in traditional molecules and making it easier to tackle the advent of biosimilars. They are resorting to mergers and acquisitions as well as partnership and collaboration activities with top-tier players, highly innovative small and medium-sized biotech companies, governmental institutions and leader venture capitals to gain access to the latest developments in monoclonal antibody therapeutics.
"Partnership deals and agreements are adding impetus to technology synergy," concluded Van Cauwenberghe. "As a result, high-potency products such as ultrapotent antibodies obtained by replacing amino acids, bispecific antibodies and antibody fragments, as well as, glycoengineered antibodies and other innovative solutions are gaining increasing attention."
Advances in Monoclonal Antibody Therapeutics, a part of the TechVision (http://ww2.frost.com/research/technology/health-wellness) subscription, provides expert opinions on the emerging trends in monoclonal antibody therapeutics globally, through a detailed strategic assessment of the industry environment.
Frost & Sullivan's global TechVision practice is focused on innovation, disruption and convergence and provides a variety of technology based alerts, newsletters and research services as well as growth consulting services. Its premier offering, the TechVision program, identifies and evaluates the most valuable emerging and disruptive technologies enabling products with near-term potential. A unique feature of the TechVision program is an annual selection of 50 technologies that can generate convergence scenarios, possibly disrupt the innovation landscape, and drive transformational growth. View a summary of our TechVision program by clicking on the following link: http://ifrost.frost.com/TechVision_Demo.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.
Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.
For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?
Advances in Monoclonal Antibody Therapeutics
D65E
Contact:
Kayla Belcher
Corporate Communications – North America
P: +1.210.247.2450
F: +1.210.348.1003
E: kayla.belcher@frost.com
http://www.frost.com/techvision
Share this article